Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone

Australas J Dermatol. 2020 May;61(2):170-171. doi: 10.1111/ajd.13196. Epub 2019 Nov 14.

Authors

Jared Marc John¹, Rodney Daniel Sinclair¹

Affiliation

¹ Sinclair Dermatology, East Melbourne, Victoria, Australia.

PMID: 31729012
DOI: 10.1111/ajd.13196

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Male
Middle Aged
Penile Diseases / complications
Penile Diseases / diagnosis
Penile Diseases / drug therapy*
Polymyalgia Rheumatica / complications
Polymyalgia Rheumatica / diagnosis
Polymyalgia Rheumatica / drug therapy*
Pyoderma Gangrenosum / complications
Pyoderma Gangrenosum / diagnosis
Pyoderma Gangrenosum / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab